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Abstract
To promote cancer research and to develop innovative therapies, refined pre-clinical mouse tumor models that mimic the
actual disease in humans are of dire need. A number of neoplasms along the B cell lineage are commonly initiated by a
translocation recombining c-myc with the immunoglobulin heavy-chain gene locus. The translocation is modeled in the
C.129S1-Ighatm1(Myc)Janz/J mouse which has been previously engineered to express c-myc under the control of the
endogenous IgH promoter. This transgenic mouse exhibits B cell hyperplasia and develops diverse B cell tumors. We have
isolated tumor cells from the spleen of a C.129S1-Ighatm1(Myc)Janz/J mouse that spontaneously developed a plasmablastic
lymphoma-like disease. These cells were cultured, transduced to express eGFP and firefly luciferase, and gave rise to a highly
aggressive, transplantable B cell lymphoma cell line, termed IM380. This model bears several advantages over other models
as it is genetically induced and mimics the translocation that is detectable in a number of human B cell lymphomas. The
growth of the tumor cells, their dissemination, and response to treatment within immunocompetent hosts can be imaged
non-invasively in vivo due to their expression of firefly luciferase. IM380 cells are radioresistant in vivo and mice with
established tumors can be allogeneically transplanted to analyze graft-versus-tumor effects of transplanted T cells.
Allogeneic hematopoietic stem cell transplantation of tumor-bearing mice results in prolonged survival. These traits make
the IM380 model very valuable for the study of B cell lymphoma pathophysiology and for the development of innovative
cancer therapies.
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Introduction
To assess the efficacy of novel anti-cancer therapies, refined pre-
clinical mouse models that mimic the actual disease in humans
need to be developed [1]. Translocations recombining C-MYC at
8q24 with the immunoglobulin heavy-chain gene locus, IGH, at
14q32 (8;14)(q24;q32) in B cells are seen as the initiating genomic
event in Burkitt’s lymphoma [1–5] and this translocation is also
observed in other aggressive B cell tumors such as acute
lymphoblastic leukemia [6,7] and plasmacytoma/multiple myelo-
ma [8,9]. The (8;14)(q24;q32) translocation is modeled in the
C.129S1-Ighatm1(Myc)Janz/J mouse [10]. Tumor-free heterozygous
mice exhibit increased B cell proliferation and apoptosis and have
enlarged lymph nodes and spleen due to follicular hyperplasia.
More than two thirds of these mice develop mature B cell tumors
between the age of 6 and 21 months resembling human endemic
Burkitt’s lymphoma or plasmacytoma [10].
To reliably evaluate the response of deep-tissue tumors
dynamically, non-invasive imaging techniques have gained wide-
spread acceptance, and among these, bioluminescence imaging
has proven a valuable tool to assess tumor growth in vivo [11–14].
In the current study, we have isolated tumor cells from the spleen
of a C.129S1-Ighatm1(Myc)Janz/J mouse that spontaneously developed
a plasmablastic lymphoma-like neoplasia. The cells were transduced
to stably express eGFP and firefly luciferase and gave rise to a highly
aggressive, transplantable B cell lymphoma cell line, termed IM380.
Exploiting in vivo bioluminescence imaging, we could assess homing
of lymphoma cells to lympho-hematopoietic compartments and
their response to allogeneic stem cell transplantation.
Materials and Methods
Ethics statement
All experiments were performed according to the German
regulations for animal experimentation. The study was approved
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by the Regierung von Unterfranken as the responsible authority
(Permit Number 55.2-2531.01-103/11). All procedures were
performed under esketamine/xylazine anesthesia, and all efforts
were made to minimize suffering.
Animals
BALB/c and C57Bl/6 mice were obtained from Charles River
(Sulzfeld, Germany). C.129S1-Ighatm1(myc)Janz/J (in BALB/c H-2d
background) mice expressing mouse c-myc under the control of
the endogenous immunoglobulin heavy-chain 2 C-alpha locus
[10] were initially obtained from Jackson Laboratories (Bar
Harbor, ME, USA). Female BALB/c and C57Bl/6 mice were
used for experiments between 8 and 12 weeks of age. All mice
were kept within the specified pathogen-free animal facility of the
Center for Experimental Molecular Medicine at the Wu¨rzburg
University Hospital receiving rodent chow and autoclaved
drinking water ad libitum.
Isolation of bone marrow cells and splenic T cells from
C57Bl/6 mice
Bone marrow cells were isolated by flushing femur and tibia
bones with phosphate buffered saline (PBS). The cell suspension
was filtered through a 70 mm cell strainer (BD, Heidelberg,
Germany). Spleens were directly filtered through a 70 mm cell
strainer into erythrocyte lysis buffer (168 mM NH4Cl, 10 mM
KHCO3, 0.1 mM ethylenediaminetetraacetic acid (EDTA)),
incubated for 2 minutes, and 2 volumes of PBS were added to
the single cell suspension. The cells were spun down; the cell pellet
was resuspended in PBS and filtered through a new 70 mm cell
strainer, before being spun down again. The resulting pellet was
resuspended in PBS and cells were used for further experiments. T
cells were enriched from splenocytes using the Dynal Mouse T cell
Negative Isolation Kit (Invitrogen, Darmstadt, Germany) accord-
ing to the manufacturer’s instructions.
Generation of a luciferase-expressing malignant
plasmablastic lymphoma-like B cell line
C.129S1-Ighatm1(myc)Janz/J mice exhibit B cell hyperprolifera-
tion and develop B cell and plasma cell neoplasms, the incidence
of which increases with age [10]. Splenocytes from a five months
old female moribund mouse (internal number 380) were isolated
and cultured in RPMI medium supplemented with 10% fetal
bovine serum (FBS), 1% antibiotics (penicillin, streptomycin), L-
glutamine and 0.1% b-mercaptoethanol (cRPMI) for six weeks
and passaged once weekly to allow malignant clones to emerge.
For lentiviral transduction, 293 T cells were transiently transfected
with a standard calcium phosphate precipitation protocol in 10 cm
dishes using 10 mg pMDL and 5 mg RSV-REV packaging
plasmids, 6 mg VSV/G envelope plasmid and 20 mg of the target
plasmid FUGLW (FUGW plasmid (Addgene, Cambridge, MA)
with the firefly luciferase inserted into it). Two days later, the
supernatant containing the lentiviral particles was harvested,
filtered through a 0.45 mm filter, 8 mg polybrene/ml were added
and the mixture was used to transduce the IgH-myc tumor cells.
The transduced cells were flow sorted twice for eGFP-expression
and were termed IM380 (IgH-myc-induced lymphoma 380). For
in vivo experiments, 105 IM380 cells in 100 ml PBS were injected
into the lateral tail vein of female syngeneic BALB/c mice.
Immunoglobulin typing
The immunoglobulin isotype of IM380 cells was determined
using the IsoQuick Kit for Mouse Monoclonal Antibodies (Sigma,
Schnelldorf, Germany) according to the manufacturer’s instruc-
tions.
Cytotoxicity assay
IM380 cells were cultured in 96 well plates for 48 h with
different concentrations of various cytotoxic drugs before staining
with annexin V-Pacific Blue (Biolegend, Fell, Germany) and
propidium iodide and flow cytometry. Survival rates for treated
cultures were normalized to the survival rate of untreated cultures
to generate survival inhibition curves and to calculate IC50-values
for the individual drugs [14]. To assess for cytotoxic killing of
tumor cells (H-2d) by allogeneic C57Bl/6 (H-2b) T cells, T cells
were isolated and activated with aCD28 (2 mg/ml) and plate-
bound aCD3 for 48 h. IM380 cells (5000 per well) were co-
cultured with activated T cells at indicated ratios for 72 h in a
round bottom 96-well plate. Tumor cell numbers were assessed by
their in vitro bioluminescence.
Allogeneic stem cell transplantation and
graft-versus-tumor model
Tumor-bearing BALB/c mice were lethally irradiated using a
Faxitron CP-160 X-ray irradiation system (Faxitron X-Ray,
Lincolnshire, IL, USA) with a dose of 8 Gy [15] six days after
tumor cell inoculation. Irradiated mice were injected with 56106
allogeneic bone marrow cells and 56105 enriched T cells isolated
from C57Bl/6 donor mice intravenously into the retro-orbital
plexus. Mice were treated with antibiotic drinking water (Baytril,
Bayer, Leverkusen, Germany) for one week to prevent infections
following lethal irradiation.
In vivo and ex vivo bioluminescence imaging
For in vivo bioluminescence imaging [15,16], mice were
anesthetized with an intraperitoneal injection of 80 mg/kg body
weight (bw) esketamine hydrochloride (Pfizer, Berlin, Germany)
and 16 mg/kg bw xylazine (cpPharma, Burgdorf, Germany).
Together with anaesthetics, mice were injected with 300 mg/kg
bw D-luciferin (Biosynth, Staad, Switzerland). Ten minutes later,
bioluminescence signals of the anesthetized mice were recorded
using an IVIS Spectrum imaging system (Perkin-Elmer/Caliper
Life Sciences, Mainz, Germany). Pictures were taken from the
ventral view in automatic mode with a maximum exposure time of
five minutes per picture. For ex vivo imaging, mice were injected
with D-luciferin and euthanized 10 minutes later. Internal organs
were removed and subjected to ex vivo bioluminescence imaging.
Pictures were evaluated using Living Image 4.0 software (Caliper
Life Sciences). Tissue samples were fixed in 4% PFA, bones were
subsequently decalcified for 72 h in EDTA (Titriplex, VWR,
Ismaning, Germany) and embedded in paraffin for further
histopathological evaluation. 2 mm sections were stained with
haematoxylin/eosin and representative pictures were taken using a
Nikon Eclipse E600 microscope and a Nikon DS-Fi1 camera.
Flow cytometry
Cells were blocked with normal rat serum (1:20 in PBS) and
stained with appropriate antibodies at 4uC for 30 min. For
intracellular stainings, cells were fixed and permeabilized using
Fixation/Permeabilization Concentrate and Diluent from
eBioscience (Frankfurt, Germany). Antibodies were obtained from
either eBioscience, Biolegend, Bioss (Woburn, MA, USA), or BD
(Heidelberg, Germany): B220-Biotin (RA3-6B2), BCL6-PE
(mGI191E), CD10-PE/Cy7 (bs-0527R), CD138-Biotin (281-2),
CD19-APC (6D5), CD20-APC (2H7), CD27-PE (LG.7F9), CD29-
PE (HMb1-1), CD38-Alexa647 (90), CD44-PE (IM7), CD49d-
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Alexa647 (RI-2), CD54-PE (YN1/1.7.4), H-2kd-Biotin (SF1-1.1),
I-Ad-Biotin (39-10-8). Biotinylated antibodies were detected with
Streptavidin-Alexa647 (Invitrogen). All experiments were analyzed
on a BD FACS Canto II (BD) and sample data was recorded using
BD FACS Diva software and analyzed using FlowJo software
(Tree Star, Ashland, OR, USA).
Statistics
The number of animals is indicated in the figure legends. All
data are shown as mean 6 standard error of mean (S.E.M.).
Figures were prepared with GraphPad Prism 5 software (La Jolla,
CA, USA) and Adobe Photoshop 7 (San Jose, CA, USA). All
groups were compared to the respective control group by two-
tailed unpaired student’s t-test with GraphPad InStat 3 software.
Data reaching statistical significance are indicated as: * p$0.05, **
p$0.01.
Results and Discussion
We isolated splenocytes from an enlarged spleen of a moribund
5 months old heterozygous C.129S1-Ighatm1(Myc)Janz/J mouse and
subcultured these cells for six weeks. The primary tumor in the
spleen and as an abdominal tumor mass showed a starry sky-like
appearance indicative of widespread apoptosis and infiltrating
macrophages often associated with Burkitt’s lymphoma [17] but
also not uncommon in plasmablastic lymphomas and advanced-
stage plasmacytomas [18,19] (Figure 1A). The cultured IM380
cells doubled each 20.166.1 hours, they produced IgM antibodies
with the k light chain (data not shown). To characterize the
immunophenotype of IM380 cells, we assessed the expression of a
number of B cell markers and activation-associated surface
proteins (Figure 1B). The cells expressed the pan-B cell markers
B220 and CD19, but were only slightly positive for the plasma cell
marker CD138. They expressed BCL6 but were negative for
CD10, two markers commonly expressed by Burkitt’s lymphoma
[20]. IM380 cells stained negative for the B cell marker CD20,
negative for CD27 which is expressed on plasma cells, and positive
for the activation markers CD29, CD38, CD44, CD49d, and
CD54. Loss of CD20 expression is rare in B cell lymphomas and
associated with higher aggressiveness [21,22]. Burkitt’s lymphomas
usually do not express CD138 [23–25] or CD44 [26,27].
Lymphoblastic lymphoma usually co-expresses CD10 and CD19
but show variable expression of CD20 [28,29]. In summary, the
immunophenotype of IM380 cells indicates them to be of an origin
intermediate of mature B cells and plasma cells.
We next tested the responsiveness of IM380 cells towards a
panel of chemotherapeutic drugs in vitro by the use of Annexin V/
propidium iodide staining (Figure 1C). The cells displayed a
spontaneous cell death rate of about 10–25% and were found to be
especially sensitive towards treatment with vincristine, bortezomib,
panobinostat, etoposide, decitabine, and doxorubicin. The cells
were positive for H-2kd (MHC class I) but negative for I-Ad (MHC
class II). Pre-activated, but not naı¨ve allogeneic C57Bl/6 T cells
effectively killed IM380 cells in vitro (Figure 1D and data not
shown).
To determine the in vivo homing and growth characteristics of
the new IM380 cell line, we transduced the cells to stably express
eGFP and firefly luciferase. Subsequently, we injected syngeneic,
immunocompetent BALB/c mice with 105 IM380 cells i.v. and
monitored lymphoma homing and progression by non-invasive
bioluminescence imaging (Figure 2A and B). IM380 lymphoma
cells grew in the bone marrow compartment and within secondary
lymphatic organs (spleen and lymph nodes). Tumor cell signals
could be detected in vivo as early as two days after injection (data
not shown). Over the course of the experiment, additional tumor
foci could be detected which speaks for tumor dissemination of the
IM380 cells as they spread from their initial sites of growth
(Figure 2C). Ex vivo bioluminescence imaging of internal organs
and hind legs (Figure 2D) showed strong tumor cell infiltration of
secondary lymphatic organs (spleen.cLN.mLN.iLN), bone
marrow, lungs, thymus, and pancreas. Involvement of spleen
and bone marrow could also be confirmed by histology (Figure 2E).
To address whether the IM380 cell line is suitable for graft-
versus-tumor studies, we transplanted BALB/c mice with pre-
existing tumors with allogeneic C57Bl/6 bone marrow and
enriched T cells. Lethal irradiation as a pre-transplantation
conditioning regimen of tumor-bearing mice resulted in tumor
regression that lasted only for about four days after which the
tumor relapsed and progressed. The same held true for mice that
were irradiated and transplanted with allogeneic bone marrow
cells. Transplantation with allogeneic T cells on the other hand
resulted in efficient tumor eradication (Figure 3A and B) and
prolonged survival when compared to the other groups (Figure 3C)
(median survival: irradiation+bone marrow: 17 days, irradia-
tion+bone marrow+T cells: 36.5 days; p,0.0001 as assessed by
Log-rank (Mantel-Cox) test). Half of the mice (5/10) that were
transplanted with allogeneic T cells nevertheless eventually
succumbed to the tumor within 40 days after allogeneic
transplantation owing to its high aggressiveness. Whereas activated
allogeneic T cells are capable of killing IM380 cells in vitro, the
tumor cells appear to develop immune escape variants in vivo
resulting in tumor relapse [30,31].
The IgH-myc translocation has been mimicked in mouse
models before. The challenge there is that the arising tumors are
very heterogenous and furthermore, the time to onset of disease
varies enormously both within and between the different mouse
models [10,32]. Whereas xenogenic tumor models bear relevance
in terms of responsiveness of human cancer to therapy, they
completely ignore the contribution of a functional immune system
to tumor control on the one hand, and tumor-induced immune
suppression on the other. These facts very much limit the
applicability of such models in preclinical drug testing. Inoculated
IM380 tumors behave in a highly reproducible manner and they
arise in immunocompetent host mice which makes the IM380 cell
Figure 1. Generation of the malignantIgH-myc-driven plasmablastic lymphoma-like B cell line IM380. A: Photomicrograph of the initial
tumor in a five months old C.129S1-Ighatm1(Myc)Janz/J mouse. The abdominal tumor mass shows starry sky-like areas indicative of widespread
apoptosis and infiltrating macrophages. The left picture shows 1006 and the right picture 4006magnification, H and E staining. B: Malignant
splenocytes were cultured in vitro and gave rise to the IM380 cell line that was characterized for its expression of various B cell markers and
activation-associated proteins by flow cytometry. (Representative results from at least two independent experiments). C: IM380 cells were treated in
vitro with different chemotherapeutics for 48 h before being subjected to annexin V/propidium iodide staining. Upper panel: Exemplary flow
cytometry data for etoposide treatment. Lower panel: The graph shows the sensitivity of the cells towards the different compounds, expressed as
their respective IC50-values. (Mean 6 SEM; combined data from four independent experiments). D: Luciferase-transgenic IM380 tumor cells were co-
cultured with activated T cells for 72 h. Tumor cell numbers were assessed by their in vitro bioluminescence (upper panel and graphic evaluation in
lower panel). Co-cultures were set up in triplicates each and compared to the 1:1 culture. Flow cytometric assessment of MHC expression on IM380
cells. (Representative results from two independent experiments).
doi:10.1371/journal.pone.0081320.g001
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line very valuable in the development of efficient anti-tumoral
therapies. A number of drugs are currently successfully used for
the treatment of aggressive B cell lymphomas [33,34]. In vitro drug
testing revealed several of these drugs also to be functional in
killing IM380 cells (e.g. vincristine, methotrexate, doxorubicine,
and etoposide). We have furthermore identified a number of drugs
that are promising as cytotoxic agents for these cells (e.g.
bortezomib and panobinostat).
Figure 2. Non-invasive assessment of in vivo tumor growth and dissemination. A: 105 luciferase-transgenic IM380 tumor cells were injected
i.v. into the lateral tail vein into syngeneic BALB/c mice. Tumor growth was assessed by non-invasive in vivo BLI at the indicated time points. B:
Representative BLI pictures of tumor-bearing mice. C: Tumor dissemination was determined by counting individual light-emitting tumor foci. D:
Upper panel: Representative ex vivo BLI picture of a tumor bearing mouse (lu: lung, cLN: cervical lymph nodes, thy: thymus, hea: heart, ki: kidney, iLN:
inguinal lymph nodes, li: liver, fe: femur, ti: tibia, sb: small bowel, lb: large bowel, mLN: mesenteric lymph nodes, st: stomach, cae: caecum, spl: spleen).
Lower panel: Evaluation of tumor cell infiltration in individual organs. A–D: (Mean 6 SEM; n = 5; shown is one representative experiment out of two).
E: Representative eosin and hematoxylinstainings of organs from tumor bearing mice shown in 2006magnification.
doi:10.1371/journal.pone.0081320.g002
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Other B cell lymphoma cell lines, be they of human or murine
origin, have arisen either spontaneously or are the result of
unspecific genotoxic insults [35]. The novel IM380 cell line results
from a single genetic event, namely the IgH-myc translocation and
thereby allows for the study of secondary mutations and clonal
evolution [36].
In summary, this new murine tumor cell model has a number of
advantages over other models [35]: 1. It is genetically induced and
mimics the translocation that is responsible for the majority of
human Burkitt’s lymphoma as well as other B cell neoplasias. 2.
The tumors arising from IM380 inoculation in vivo are highly
homogenous and reproducible. 3. Growth, dissemination, and
response to treatment can be imaged non-invasively in vivo due to
the expression of firefly luciferase by the tumor cells. 4. Established
tumors can be allogeneically transplanted to study graft-versus-
tumor effects of transplanted T cells as well as tumor cell immune
escape. Nevertheless, the IM380 cell line is highly aggressive in vivo
as mice succumb to it within less than three weeks following i.v.
inoculation, established tumors are radiation-resistant and alloge-
neic transplantation is not sufficient to eradicate the tumors in all
mice. These traits make the IM380 model highly valuable for the
study of B cell lymphoma pathophysiology, disease progression in
immunocompetent hosts and their response to treatment, and
particularly for the development of innovative cancer immuno-
therapies.
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Figure 3. Allogeneic hematopoietic stem cell transplantation of tumor-bearing mice results in prolonged survival. 105 luciferase-
transgenic IM380 tumor cells were injected i.v. via the lateral tail vein into syngeneic BALB/c mice. Six days after tumor cell inoculation, mice were
lethally irradiated with 8 Gy and transplanted with 56106 bone marrow cells and 0.56106 enriched splenic T cells from C57Bl/6 mice. A and B: Tumor
growth was assessed by non-invasive in vivo BLI at the indicated time points (Mean 6 SEM; n = 5; shown is one representative experiment out of
two). C: Survival after allogeneic transplantation (n = 9–10; combined data from two independent experiments).
doi:10.1371/journal.pone.0081320.g003
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